Back to Search
Start Over
Subconjunctival Aflibercept for the Treatment of Formed Corneal Neovascularization
- Source :
- Eye & Contact Lens: Science & Clinical Practice. 47:180-184
- Publication Year :
- 2020
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2020.
-
Abstract
- Purpose To evaluate the effect of a single subconjunctival aflibercept injection on formed corneal neovascularization. Methods A prospective clinical trial, conducted at a single tertiary medical center. Included were consecutive patients with corneal pathologies complicated by corneal neovascularization, who were candidates for anti-vascular endothelial growth factor treatment at the discretion of a cornea specialist. A single subconjunctival injection of 0.08 mL of Aflibercept (Eylea 25 mg/mL) was administered near the limbus in proximity to the areas of maximal pathological neovascularization. Follow-up visits were scheduled on days 7, 30, 60, and 90 following injection. Best-corrected visual acuity (BCVA), intraocular pressure, slitlamp examination, digital cornea photography, specular microscopy, and anterior-segment optical coherence tomography were documented at each visit. The images were graded by a masked observer for density, extent, and centricity of corneal vascularization. Results Six eyes of six patients were analyzed. No clinically significant ocular or systemic adverse events were documented. No change was noted in extent, density, or centricity of corneal blood vessels at seven, 30, and 90 days after injection (P>0.1 for all time point comparisons, Friedman test). Best-corrected visual acuity fluctuated insignificantly in 5/6 patients during follow-up time, and objective but not subjective improvement of BCVA was noted in one patient with no concurrent change of neovascularization. The recruitment has therefore halted prematurely. Conclusions A single subconjunctival aflibercept injection seems to be well tolerated. However, it is ineffective for regressing formed corneal neovascularization.
- Subjects :
- Vascular Endothelial Growth Factor A
Intraocular pressure
medicine.medical_specialty
Visual acuity
genetic structures
Recombinant Fusion Proteins
Angiogenesis Inhibitors
Neovascularization
Cornea
Ophthalmology
Humans
Medicine
Corneal Neovascularization
Prospective Studies
Adverse effect
Aflibercept
business.industry
medicine.disease
eye diseases
Bevacizumab
Clinical trial
Receptors, Vascular Endothelial Growth Factor
medicine.anatomical_structure
Corneal neovascularization
sense organs
Injections, Intraocular
medicine.symptom
business
medicine.drug
Subjects
Details
- ISSN :
- 15422321
- Volume :
- 47
- Database :
- OpenAIRE
- Journal :
- Eye & Contact Lens: Science & Clinical Practice
- Accession number :
- edsair.doi.dedup.....82acd1c927bd3da07b544544bb4def34